15P HRD status and mutation concordance using ascites-derived cfDNA in high-grade serous ovarian cancer (HGSC): Impact of sample type, cytology and treatment setting

July 1, 2026ESMO OpenOpen Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to explore the effectiveness of cfDNA from ascites in determining HRD status and genomic alterations in high-grade serous ovarian cancer.
Analyzed cfDNA samples extracted from ascites supernatant and cell pellet.
Examined HRD status and genomic alterations in high-grade serous ovarian cancer patients.
Compared results between traditional tumor biopsies and ascites-derived samples.
Ascites-derived cfDNA significantly improved the detection of HRD status compared to standard biopsies.
Approximately 90% of cases yielded informative HRD results using cfDNA from ascites.
The use of both supernatant and cell pellet enhanced mutation concordance.

Shows improved HRD analysis in high-grade serous ovarian cancer using ascites-derived cfDNA, indicating better clinical outcomes.

No abstract yet. The journal hasn't published one we can show.

No takes yet. Share an insight, caveat, or question.

Saux et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share